We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Liso-cel

News List

Bristol Myers faces $6.4bn lawsuit over cancer drug delay pharmaceutical-technology
June 07, 2021
UMB Bank, a trustee for Celgene’s former shareholders, has filed a lawsuit against Bristol Myers Squibb (BMS) for allegedly delaying the development and manufacturing of cancer drug lisocabtagene maraleucel (Liso-cel) to avoid contingent value right (CVR)
USFDA extends review of Bristol Myers’ cancer therapy acquired in Celgene deal expresspharma
May 07, 2020
The company said it had submitted additional information on the therapy known as liso-cel, which was considered a major amendment to the marketing application by the agency.
Bristol-Myers Squibb’s Liso-Cel meets key endpoints in blood cancer trial pharmaceutical-business-review
December 11, 2019
Bristol-Myers Squibb announced that its blood cancer treatment lisocabtagene maraleucel (liso-cel) has achieved its primary and secondary endpoints in TRANSCEND NHL 001 study.